Science AI Journal
Medicine · Research topic

Open research questions in SARS-CoV-2 and COVID-19 Research

241 unresolved questions extracted from the limitations and future-work sections of 1,049 SARS-CoV-2 and COVID-19 Research papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • The study identifies a gap in understanding the seroprevalence of SARS-CoV-2 in Barcelona and Catalonia after the 2020 lockdown. The study aims to fill this gap by assessing SARS-CoV-2 seroprevalence in a large sample of individuals.

    SARS-CoV-2 seroprevalence in Barcelona and Catalonia (Spain) after the 2020 lockdown · 2026 · DOI

  • Investigating the molecular mechanisms of C activation and production of proinflammatory cytokines in vivo, - Elucidating the structure-function relationship regarding nucleic acid-induced C activation

    mRNA-LNP COVID-19 Vaccine Lipids Induce Complement Activation and Production of Proinflammatory Cytokines: Mechanisms, Effects of Complement Inhibitors, and Relevance to Adverse Reactions · 2024 · DOI

  • The mechanism of adverse events caused by mRNA-LNP COVID-19 vaccines has not been clarified to date. There is a lack of understanding of the molecular mechanisms of these adverse events.

    mRNA-LNP COVID-19 Vaccine Lipids Induce Complement Activation and Production of Proinflammatory Cytokines: Mechanisms, Effects of Complement Inhibitors, and Relevance to Adverse Reactions · 2024 · DOI

  • Many details of SARS-CoV-2 infection are not fully understood, including the cell biology and host-virus interactions involved in coronavirus assembly and release, in which the Envelope (E) structural protein is instrumental.

    Deletion of the Envelope gene attenuates SARS-CoV-2 infection by altered Spike localization and increased cell-to-cell transmission · 2026 · DOI

  • However, how this condensate becomes selectively enveloped by a membrane remains unclear.

    SARS-CoV-2 maturation driven by a mechano-active nucleocapsid-RNA condensate · 2026 · DOI

  • However, there is no standard neutralization assay, and absolute titers differ between assays.

    Reconciliation of titer differences between SARS-CoV-2 neutralizing antibody assays · 2026 · DOI

  • CONCLUSIONS: During the study period, most COVID-19 cases in Victoria received antivirals but variations according to age, sex, socioeconomic status, residence in aged care and vaccination suggest that further efforts to identify barriers and enablers to treatment are warranted.

    Patterns of use of oral antivirals for COVID-19 in people 70 years and over in Victoria, Australia: a linked data study · 2026 · DOI

  • Protein-coding circular RNA (circRNA) is an emerging class of RNA cargo that offers increased stability compared to mRNA with potentially reduced immunogenicity, but delivery technologies for intracellular delivery of circRNA remain underexplored.

    Circular RNA lipid nanoparticle vaccine against SARS-CoV-2 · 2025 · DOI

  • While the clinical significance of P3 in COVID-19 remains unclear, its homology to other mammalian proteins suggests a potential role for this peptide family in human inflammation and autoimmunity.

    The identification of a SARs-CoV2 S2 protein derived peptide with super-antigen-like stimulatory properties on T-cells · 2025 · DOI

  • Finally, an ill-defined phenomenon of prolonged symptoms after acute infection, termed "long COVID," is poorly understood but may involve various immunologic defects that are hyperactivating or immunosuppressive.

    The immunopathogenesis of SARS-CoV-2 infection: Overview of lessons learned in the first 5 years · 2025 · DOI

  • It remains unclear how non-neutralizing antibodies that target the nucleocapsid (N) protein contribute to protection against SARS-CoV-2 variants, especially their ability to trigger antibody effector functions.

    Non-neutralizing antibodies against SARS-CoV-2 nucleocapsid protein mediate variant transcendent antibody-dependent cellular cytotoxicity · 2025 · DOI

  • While a reduced absolute CD4+ T cell count is a known factor, other determinants remain unclear.

    Impact of CD4+ T cell and TCR repertoires on SARS-CoV-2-Specific antibody responses in PLWH following COVID-19 vaccination · 2025 · DOI

  • Several studies have addressed the antibody responses following the bivalent booster, but its effect on T cells remains uncertain.

    T cell responses to COVID-19 bivalent booster vaccine 2422 · 2025 · DOI

  • Whether and to which extent durable pan-coronavirus T cell responses compensate for this reduced humoral immunity is not fully understood.

    Aging and viral evolution impair pan-coronavirus immunity 2342 · 2025 · DOI

  • In immunosuppressed individuals, who are at an increased risk for severe COVID-19, the impact of immunosuppressants on Tregs and inflammatory responses in breakthrough infections remain unclear.

    Dysregulated regulatory T cell response in immunosuppressed individuals is associated with increased inflammation in COVID-19 breakthrough infections 2587 · 2025 · DOI

  • However, the susceptibility of C57BL/6 mice to recently emerged Omicron subvariants, and the role of T cell-mediated immunity in controlling these infections, remain incompletely understood.

    SARS-CoV-2 XBB.1.5 infects wild-type C57BL/6 mice and induces a protective CD4+ T cell response required for viral clearance · 2025 · DOI

  • The viral load as indicated by the Ct value varied widely, with a significant appearance in the lower ranges (high viral load), suggesting active viral replication.

    Genome diversity of SARS-CoV-2 lineages associated with vaccination breakthrough infections in Addis Ababa, Ethiopia · 2025 · DOI

  • However, the relationship between diverse vaccination statuses and the spectrum of symptom presentation, disease severity, and long-term post-COVID conditions remains to be fully understood.

    Impact of vaccination on SARS-CoV-2 infections and long COVID symptoms: a cross-sectional study in China · 2025 · DOI

  • There is limited data on their characteristics and outcomes compared to non- or partially vaccinated patients, and no studies have evaluated the impact of variants of concern.

    Comparison of fully-vaccinated and non/partially-vaccinated critically-ill COVID-19 patients in terms of disease severity: a retrospective observational study · 2025 · DOI

  • The definition of the waning kinetics of neutralizing SARS-CoV-2 responses and the potential impact of sequential antigen encounters are still poorly defined.

    Recurrent waning of anti-SARS-CoV-2 neutralizing antibodies despite multiple antigen encounters · 2025 · DOI

  • Also, future research should examine different age groups, vaccination types, and the number of doses given.

    Mortality involving and not involving COVID-19 among vaccinated vs. unvaccinated in England between Apr 21 and May 23 · 2025 · DOI

  • However, more conventional outcomes such as quality-adjusted life years (QALYs) and inequality indicators are warranted as additional information for policymakers.

    The impact of quality-adjusted life years on evaluating COVID-19 mitigation strategies: lessons from age-specific vaccination roll-out and variants of concern in Belgium (2020-2022) · 2024 · DOI

  • Geographical and Ethnic Limitations: If the study is localized to a certain place, the results may not be applicable to other populations with varying environmental or genetic characteristics.

    JN. 1 and cardiac-related clinical manifestations: a current public health concern · 2024 · DOI

  • Accessory genes influence viral host range and cellular tropism, but little is known about how selection acts on these variable regions of virus genomes.

    Hidden evolutionary constraints dictate the retention of coronavirus accessory genes · 2024 · DOI

  • Little is known about the mucosal immune response in children infected or vaccinated against SARS-CoV-2.

    SARS-CoV-2–specific mucosal immune response in vaccinated versus infected children · 2024 · DOI

Most-cited papers in SARS-CoV-2 and COVID-19 Research

Most recent work

Find a gap in your own SARS-CoV-2 and COVID-19 Research sub-topic

This page shows what the SARS-CoV-2 and COVID-19 Research literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Medicine

Artificial Intelligence in Healthcare and Education
2,044 open questions
Substance Abuse Treatment and Outcomes
1,964 open questions
Smoking Behavior and Cessation
990 open questions
Dementia and Cognitive Impairment Research
974 open questions
Innovations in Medical Education
960 open questions
Physical Activity and Health
923 open questions
Attention Deficit Hyperactivity Disorder
839 open questions
Schizophrenia research and treatment
709 open questions
241 open questions have been extracted from the limitations and future-work passages of 1,049 SARS-CoV-2 and COVID-19 Research papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.